Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Zealand Pharma
< Previous
1
2
3
4
Next >
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
August 30, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Financial Results for the First Half of 2023
August 17, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results
August 14, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396
July 03, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
June 30, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Presents Results from Phase 1 Clinical Trial of Amylin Analog ZP8396 at ADA Scientific Sessions
June 24, 2023
From
Zealand Pharma
Via
GlobeNewswire
Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)
June 23, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Financial Results for the First Quarter of 2023
May 11, 2023
From
Zealand Pharma
Via
GlobeNewswire
Boehringer Ingelheim and Zealand Pharma announce phase II trial showed 14.9% weight loss in people living with obesity or overweight
May 10, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Hosts Conference Call on May 11 at 2pm CET (8am ET) to Present First Quarter 2023 Results
May 04, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to Participate in 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion
March 30, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma announces directed issue and private placement of approximately 6.5 million new shares
March 30, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Positive Phase 1 Clinical Results with Amylin Analogue ZP8396
March 28, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
March 09, 2023
From
Zealand Pharma
Via
GlobeNewswire
Correction: Zealand Pharma convenes its Annual General Meeting 2023
March 03, 2023
From
Zealand Pharma
Via
GlobeNewswire
Correction: Zealand Pharma Announces Full Year Results for 2022
March 02, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma convenes its Annual General Meeting 2023
March 02, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Full Year Results for 2022
March 02, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to Host Conference Call on March 2, 2023 at 2 pm CET (8 am ET) to Present Full Year Results for 2022
February 24, 2023
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Announces Financial Results for the First Nine Months of 2022
November 10, 2022
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma to Participate in Upcoming Investor Conferences
November 08, 2022
From
Zealand Pharma
Via
GlobeNewswire
Zealand Pharma Hosts Conference Call on November 10 at 4pm CET (10am ET) to Present Third Quarter Results for 2022
November 03, 2022
From
Zealand Pharma
Via
GlobeNewswire
Tickers
ZEAL
Zealand Pharma Announces Presentations at The Obesity Society Annual Meeting
November 01, 2022
From
Zealand Pharma
Via
GlobeNewswire
Tickers
ZEAL
Zealand Pharma major shareholder announcement: Polar Capital
October 11, 2022
From
Zealand Pharma
Via
GlobeNewswire
Tickers
ZEAL
Zealand Pharma major shareholder announcement: Van Herk Investments
October 10, 2022
From
Zealand Pharma
Via
GlobeNewswire
Tickers
ZEAL
Zealand Pharma completes registration of capital increase
October 07, 2022
From
Zealand Pharma
Via
GlobeNewswire
Tickers
ZEAL
Zealand Pharma announces completion of a directed issue and private placement of 4,975,000 new ordinary shares raising gross proceeds of approx. DKK 786 million
October 04, 2022
From
Zealand Pharma
Via
GlobeNewswire
Tickers
ZEAL
Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares
October 04, 2022
From
Zealand Pharma
Via
GlobeNewswire
Tickers
ZEAL
Total number of shares and voting rights in Zealand Pharma at September 30, 2022
September 30, 2022
From
Zealand Pharma
Via
GlobeNewswire
Tickers
ZEAL
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today